Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression

Yu Rou Puar 1, Muthu K Shanmugam 1, Lu Fan 1, Frank Arfuso 2, Gautam Sethi 1,∗ and Vinay Tergaonkar 3,4,5,∗

1 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore; yu.rou.puar@gmail.com (Y.R.P.); phcsmk@nus.edu.sg (M.K.S.);
phcfanl@nus.edu.sg (L.F.)
2 Stem Cell and Cancer Biology Laboratory, School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6009, Australia; frank.arfuso@curtin.edu.au
3 Institute of Molecular and Cellular Biology (A*STAR), 61 Biopolis Drive, Singapore 138673, Singapore
4 Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
5 Centre for Cancer Biology (University of South Australia and SA Pathology), Adelaide, SA 5000, Australia
∗ Correspondence: phcgs@nus.edu.sg (G.S.); vinayt@imcb.a-star.edu.sg (V.T.); Tel.: +65-6516-3267 (G.S.)

Received: 27 June 2018; Accepted: 24 July 2018; Published: 27 July 2018

Abstract: Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is responsible for the regulation of a large number of genes that are involved in important physiological processes, including survival, inflammation, and immune responses. At the same time, this transcription factor can control the expression of a plethora of genes that promote tumor cell proliferation, survival, metastasis, inflammation, invasion, and angiogenesis. The aberrant activation of this transcription factor has been observed in several types of cancer and is known to contribute to aggressive tumor growth and resistance to therapeutic treatment. Although NF-κB has been identified to be a major contributor to cancer initiation and development, there is evidence revealing its role in tumor suppression. This review briefly highlights the major mechanisms of NF-κB activation, the role of NF-κB in tumor promotion and suppression, as well as a few important pharmacological strategies that have been developed to modulate NF-κB function.

Keywords: NF-κB; cancer; apoptosis; metastasis; pharmacological inhibition

1. Introduction

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a family of transcription factors that was first discovered by David Baltimore in 1986 and has recently generated considerable interest for its role in the development of a variety of human ailments. In mammalian cells, it consists of five members, namely, RelA (p65), RelB, Rel (c-Rel), NF-κB1 (p50/p105), and NF-κB2 (p52/p100) that can form both homodimers and heterodimers and play an essential role in the regulation of immune responses and inflammation [1–4]. In non-stimulated cells, NF-κB is associated with IκB proteins and resides in the cytoplasm [5–7].

2. Activation Pathways

There are various modes of NF-κB activation that have been documented in the literature [8]. The activation of NF-κB through the canonical pathway, the most widely known NF-κB pathway,
is essential for inflammation and innate immunity [9–11]. This involves the phosphorylation of the IkB protein on two conserved serine residues within its N-terminal domain. This is carried out by two IkB kinases, IKK1 and IKK2, which reside in the IKK complex. The IKK complex varies in size and composition in different cell types and can also contain non-enzymatic regulatory subunit IKKy (NEMO), which is essential for the activation of the IKK1-IKK2 heterodimer [12]. The phosphorylation of these residues leads to rapid polyubiquitination by the Skp, Cullin, F-box β-transducin repeat-containing protein (SCF-β-TrCP) complex and subsequent degradation by the 26S proteasome, activating the NF-κB signaling cascade and resulting in the complete degradation of IkB proteins [13–16]. The NF-κB dimers then undergo further modification through phosphorylation and acetylation before translocation to the nucleus where they bind to the DNA and recruit transcriptional coactivators [12,17,18] and are thus constitutively activated in various human diseases (Table 1).

Table 1. The activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in selected human diseases.

| Cancers                                      | Inflammatory Diseases                                      |
|----------------------------------------------|-------------------------------------------------------------|
| Acute lymphoblastic leukemia                 | Alzheimer’s disease                                         |
| Acute lymphoblastic lymphoma                 | Rheumatoid arthritis                                        |
| Breast                                       | Atherosclerosis                                              |
| Burkitt lymphoma                             | Multiple sclerosis                                           |
| Cervical                                     | Chronic inflammatory demyelinating Polyradiculoneuritis     |
| Colorectal                                   | Asthma                                                      |
| Diffuse large B-cell lymphoma                | Inflammatory bowel disease                                  |
| Fibrosarcoma                                  | Helicobacter pylori-associated gastritis                     |
| Head and neck                                | Systemic inflammatory response syndrome                     |
| Hodgkin’s lymphoma                           | Parkinson’s disease                                         |
| Mammary carcinoma                            |                                                            |
| Mantle cell lymphoma                         |                                                            |
| Multiple myeloma                             |                                                            |
| Lung                                         |                                                            |
| Ovarian                                      |                                                            |
| Pancreatic                                   |                                                            |
| Prostate                                     |                                                            |
| Squamous-cell carcinoma                      |                                                            |
| Thyroid                                      |                                                            |
| Vulva                                         |                                                            |

The activation of NF-κB through the non-canonical pathway is essential in lymphoid organ development and adaptive immunity [19,20], (Figure 1). This pathway involves a more restricted set of ligands, such as the B-cell-activating factor (BAFF), lymphotoxin-beta (LT-β), and cluster of differentiation 40 (CD40), which can lead to the activation of the NF-κB inducing kinase (NIK) that phosphorylates and activates the IKK1 homodimer, resulting in the phosphorylation of p100 nd the subsequent degradation to p52 [2,20,21]. Upon p100 degradation, the RelB/p50 and RelB/p52 dimers are released and translocated into the nucleus where they start the transcription of the target genes [20,22,23].

While the canonical and non-canonical pathways have been the target of the majority of the research done on NF-κB activation, there have been an increasing number of alternative mechanisms, such as IKK-independent processes, that have been shown to activate NF-κB in a manner that is completely different from that of the canonical and non-canonical pathways [2,24,25].

Most carcinogens, including cigarette smoke, alcohol, and UV light, as well as nearly all infectious agents such as human immunodeficiency virus (HIV) and Hepatitis B and C viruses, have been shown to activate NF-κB [26–32], (Table 2). Interestingly, the epidermal growth factor (EGF) has been previously shown to induce NF-κB activation by inducing tyrosine phosphorylation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα) at residue 42 [33]. While the tumor necrosis factor (TNF)-induced NF-κB activation was found to be IKK dependent, it has been shown that chemotherapeutic agents and radiation may also activate NF-κB through diverse IKK-independent mechanisms [2,11,33].
phosphorylates and activates the IKK1 homodimer, which goes on to phosphorylate p100, leading to
pathway: upon receptor engagement, NF-κB polyubiquitination and subsequent degradation by the 26S proteasome. Non-canonical signaling
the partial SCF-β-kinase 1 [KK1] (α) and IκB kinase 1 and IκB kinase 2 [IKK2] (β) are activated
through phosphorylation before proceeding to phosphorylate nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha (IκBα) gene enhancer in B-cells inhibitor, alpha (IκBα) gene enhancer
pathway: upon receptor engagement, NF-κB-inducing kinase (NIK) is activated and directly
phosphorylates and activates the IKK1 homodimer, which goes on to phosphorylate p100, leading to
the partial SCF-β-TrCP-mediated degradation of p100 to generate the p52-RelB complex.

Table 2. A list of a few important stimuli activating NF-κB.

| Class              | Inducing Stimuli                                      |
|--------------------|-------------------------------------------------------|
| Viruses            | Human immunodeficiency virus                           |
|                    | Hepatitis B virus                                     |
|                    | Human herpes virus 6                                   |
|                    | Adenovirus                                            |
| Viral products     | Double-stranded RNA                                    |
|                    | Latent membrane protein                                |
|                    | Hepatitis B viral protein HBs                          |
|                    | Middle hepatitis B virus surfaceprotein MHBs           |
| Inflammatory cytokines | Tumor necrosis factor-α                              |
|                    | Lymphotixin                                            |
|                    | Interleukin-1                                          |
|                    | Interleukin-2                                          |
|                    | Leukotriene B4                                         |
| Bacterial products | Lipopolysaccharide                                     |
|                    | Exotoxin B                                            |
|                    | Toxic shock syndrome toxin 1                          |
|                    | Muramyl peptides                                       |
| Physical stress    | UV light                                              |

Figure 1. A brief overview of canonical and non-canonical nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) activation pathways. Canonical signaling pathway: Upon receptor
engagement, IκB kinase 1 [KK1] (α) and IκB kinase 1 and IκB kinase 2 [IKK2] (β) are activated
through phosphorylation before proceeding to phosphorylate nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha (IκB) members. Phosphorylation of these residues leads
to Skp, Cullin, F-box β-transducin repeat-containing protein SCF-β-TrCP complex-mediated rapid
polyubiquitination and subsequent degradation by the 26S proteasome. Non-canonical signaling
pathway: upon receptor engagement, NF-κB-inducing kinase (NIK) is activated and directly
phosphorylates and activates the IKK1 homodimer, which goes on to phosphorylate p100, leading to
the partial SCF-β-TrCP-mediated degradation of p100 to generate the p52-RelB complex.
3. NF-κB Activation by Chemotherapeutic Agents

Several chemotherapeutic agents, including paclitaxel, vinblastine, vincristine, doxorubicin, and daunomycin have been reported to induce NF-κB activation in different cells. However, it has also been found that the nature of the genes expressed following chemotherapy-induced NF-κB activation is context dependent and this activation can result in both the expression or suppression of anti-apoptotic genes [34–37].

Topoisomerase poisons found in numerous chemotherapeutic agents (actinomycin D, camptothecin, daunomycin, and etoposide), which have the common property of generating DNA strand breaks, can activate NF-κB in leukemia cells [35,38]. SN38 (7-ethyl-10-hydroxycamptothecin) and doxorubicin have been shown to trigger the activation of NF-κB through a pathway that involves the phosphorylation and degradation of IκBx [39]. Interestingly, adriamycin was also found to activate NF-κB in human small-cell lung carcinoma cells in a non-specific, dose-dependent manner, similarly involving the degradation of IκBβ [40]. Moreover, incubation of multiple myeloma cells with doxorubicin or the alkylating agent melphalan can lead to the robust activation of NF-κB activity that confers anti-apoptotic abilities to the treated cells [41].

There are conflicting reports regarding the role of the different IKK subunits in the NF-κB activation induced by doxorubicin [11,42,43]. On the one hand, it has been shown that TAK1 is required for doxorubicin-induced NF-κB activation, with doxorubicin inducing Lys63-linked TAK1 polyubiquitination at the lysine 158 residue during the initial stages of treatment [44]. Interestingly, at the later stage of doxorubicin exposure, Lys48-linked TAK1 polyubiquitination was observed to induce TAK1 degradation. However, it has also been reported that NF-κB complexes produced through doxorubicin-induced NF-κB activation may contribute to the suppression of constitutive- and cytokine-induced NF-κB dependent transcription. RelA produced through this pathway is not phosphorylated or acetylated and is responsible for blocking NF-κB signaling in a histone deacetylase-independent manner. In addition to this, upon doxorubicin-induced NF-κB activation, this transcription factor may no longer remain stably bound to κB elements in vivo; thus, suggesting that doxorubicin-induced NF-κB activation may not necessarily contribute to the anti-apoptotic activity in cancer cells [45].

Microtubule-disrupting agents have also been found to activate NF-κB in diverse models. Both paclitaxel and vinca alkaloids were found to induce NF-κB activation through the degradation and down-regulation of IκBx [35,46]. Paclitaxel is known to induce TNF and interleukin-1 expression in a manner that is similar to that of lipopolysaccharides, which can induce NF-κB activation via a pathway that involves TNF expression; hence, it has been proposed that paclitaxel-induced NF-κB activation utilizes a similar pathway. However, anthracyclines and vinca alkaloids are similarly able to induce NF-κB activation despite not up-regulating TNF or interleukin-1 gene expression, thus, suggesting that chemotherapy-induced NF-κB activation may not always involve cytokine up-regulation [35]. Thus, chemotherapeutic agents have been reported to modulate NF-κB activation by diverse molecular mechanism(s).

4. NF-κB Activation by Radiation

There are numerous studies supporting the involvement of ionizing radiation (IR) in the activation of NF-κB and the development of anti-apoptotic abilities in cancer cells [35,47–60]. IR-induced NF-κB activation has been observed to be initiated by the proteasomal degradation and phosphorylation of IκBx by the IKK complex [61].

It has been shown that the IR sensitivity of tissues towards the activation of NF-κB in vivo is context dependent and varies depending on the type of tissue [35]. The IR doses required for maximal NF-κB activation vary greatly depending on the cell lines or systems analyzed, ranging from 0.5 GY to over 20 GY [62,63]. There are contrasting observations of NF-κB activation following whole body irradiation at different IR doses [50,51]. NF-κB activation by IR (8.5 GY) has been shown to be tissue-specific and only detectable in the bone marrow, lymph nodes, and spleen [50]. However,
another report demonstrated the activation of NF-κB in the liver and kidney when mice were exposed to 20 Gy of IR [64]. These diverse findings suggest that different normal tissues possess differential IR sensitivities towards the activation of NF-κB.

It has been proposed that a possible mechanism through which IR induces NF-κB activation involves nuclear DNA damage and a pathway similar to the one used by camptothecin, an anti-cancer agent, that causes DNA double-stranded breaks that trigger a signaling cascade that results in the degradation of IκBα and the activation of NF-κB [65]. Interestingly, other studies have indicated that IκBα degradation was not observed in response to ionizing radiation exposure in cells from patients with ataxia-telangiectasia [49,66].

DNA-dependent protein kinase (DNA-PK) has also been shown to be essential for IR-induced NF-κB activation [48]. There are conflicting reports regarding the role of the IκB kinase complex, and the phosphorylation and degradation of IκB by the ubiquitin-proteasome pathway to release active NF-κB when cells are exposed to different doses of IR in differential cell systems [35,64,67–69].

While it has been shown that both exposure to short wavelength UV (UV-C) and gamma radiation induces NF-κB activation through a ubiquitin/proteasome pathway, UV-C-induced NF-κB activation was found to involve the degradation of IκB through phosphorylation at Ser-32 and Ser-36, leading to the activation of IKK, whereas gamma rays-induced NF-κB activation was found to utilize a different pathway; thus, suggesting that both types of radiation may utilize two different mechanisms to activate NF-κB [51]. Constitutive nitric oxide synthase activation following IR in a therapeutic dose range has been shown to cause the nitration and dissociation of IκBα tyrosine 181 from NF-κB in a process that does not involve the phosphorylation or degradation of IκBα [70].

While the activation of NF-κB has long been associated with anti-apoptotic abilities in cancer cells, NF-κB has been found to be required for cell death following UV stimulation. The exposure of U2OS bone osteosarcoma cells to UV stimulation triggered the activation of NF-κB as well as the induction of p53. However, this UV-induced NF-κB was found to be transcriptionally inert, suggesting that p53 may have a role to play in the switching of NF-κB from its usual anti-apoptotic role to a pro-apoptotic role within the cell, possibly due to its ability to sequester transcriptional co-activator proteins such as p300/CREB [35,71].

The activation of NF-κB by UV-irradiation occurs in two phases; with the early phase peaking with the greatest level of DNA binding observed at 4 h post-irradiation and the late phase occurring between 16 and 48 h post-irradiation [58]. Although IκBα depletion was observed during the late-phase of UV-irradiation, neither the ubiquitination nor the proteasomal cleavages were reported to have detectable attributions to the late-phase IκBα depletion. Instead, it has been suggested that the late phase activation of NF-κB may be regulated through a protein kinase A (PKA)/mitogen- and stress-activated protein kinase (MSK) pathway [35,58]. Overall, the exposure to radiation can regulate NF-κB activation through different modes of actions.

5. NF-κB Signaling Pathway in Inflammation

The NF-κB pathway has long been associated with inflammation due to its activation by pro-inflammatory cytokines as well as its involvement in the activation of numerous pro-inflammatory genes [20,23]. Inflammation triggered both by hepatitis and cancer progression has been shown to up-regulate TNFα, a pro-inflammatory cytokine, in Md2-knockout mice. While the inhibition of NF-κB had no effect on the development of transformed hepatocytes in the liver of the mice, the suppression of NF-κB was shown to promote the apoptosis of transformed hepatocytes and prevented the progression to hepatocellular carcinoma, suggesting that NF-κB plays a crucial role in cancer development [32,72]. However, studies have shown that the NF-κB activation is not solely pro-inflammatory and, depending on the context, can also play a part in the anti-inflammatory responses within the cells [15,16,32]. While NF-κB has been shown to initiate pro-inflammatory gene expression when activated during the onset of inflammation in leukocyte cells, interestingly, it has also been shown to be crucial for the activation of anti-inflammatory genes during the resolution of inflammation. When NF-κB activation was inhibited
during the resolution of inflammation, it was found to inhibit apoptosis and protract the inflammatory process [73].

6. NF-κB as a Tumor Promoter and Suppressor

It has been shown that the uncontrolled activation of NF-κB contributes to the initiation of tumorigenesis and plays a crucial role in tumor cell proliferation and survival [20,23,74–77], (Figure 2). NF-κB activation is essential in protecting transformed cells from macrophage-induced apoptosis during tumor initiation through the upregulation of TNF and nitric oxide [78]. In addition to playing a crucial role in tumor initiation, NF-κB has also been found to play a role in allowing cancer cells to avoid detection by the adaptive immune cells. The prolonged activation of NF-κB promotes tumorigenic proliferation and metastasis through inducing the expression of proto-oncogenes, such as c-myc and cyclin D1, as well as cell adhesion molecules, vascular endothelial growth factors (VEGFs), and matrix metalloproteinases (MMPs) [15,16]. It has been shown that the inhibition of NF-κB abolishes VEGF production and angiogenesis in a variety of conditions. Furthermore, the basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), MMP-9, and other NF-κB target genes are involved in multiple steps of angiogenesis [15,16,79,80]. It is worth noting that MMPs including MMP-2, -3, and -9 degrade the basement membrane and remodel the extracellular matrix, which facilitates cell migration and favors either angiogenesis (endothelial cells) or metastasis (cancer cells) in different microenvironment [80,81]. Interestingly, human telomerase reverse transcriptase, the catalytic subunit of telomerase [82–85] was found to drive gastric intestinal metaplasia by upregulating CDX2 (caudal type homeobox 2) expression via NF-κB signaling axis [86].

![Figure 2. A schematic diagram depicting the potential role of NF-κB in cancer initiation and progression.](image)

Morgana, a CHORDC1 gene product and a component of the IKK complex, has been shown to play an integral role in NF-κB activation and tumorigenesis. High levels of Morgana have been shown to promote tumor metastasis, induce the expression of cytokines, and suppress the presence of natural killer cells during the initial tumor growth stage as well as during the pre-metastatic stage in breast cancer mouse models, thereby promoting tumor growth and cancer progression [87]. NF-κB has also been demonstrated to play a part in the upregulation of the expression of chemokine receptor type 4 (CXCR4), a stromal cell-derived factor 1 alpha receptor, in highly metastatic breast cancer cells that contribute towards tumor growth [88,89].

The p65 and p50 NF-κB subunits were found to bind directly to the CXCR4 promoter and initiate transcription, and increased CXCR4 cell surface expression was also associated with cancer cell metastasis [88–91]. Epithelial-mesenchymal transition (EMT) is an early event in metastasis [80,92–94]. TNF-α in the tumor microenvironment acts as an inflammatory mediator that triggers the EMT of tumor cells and promotes tumor metastasis. In oral cancer cells, it promotes cell invasion and metastasis, which rely on the NF-κB signaling pathway activation [95–98]. Cell adhesion molecules
such as selectins, integrins, and their ligands can also be regulated by the NF-κB pathway [80,99], and are important in promoting cancer cell extravasation and colonization at distant sites, although the mechanistic details remain elusive [100].

However, in several specific cases, NF-κB may also function as a potential tumor suppressor. p65 has been shown to be capable of switching from its role as a tumor suppressor to a tumor promoter depending on the progression of tumorigenesis, with the regulation occurring in a cell autologous manner [78]. Interestingly, it was noted that targeted knockout of IKK2 in hepatocytes can promote the carcinogenesis in the diethylnitrosamine-induced hepatocellular carcinoma mouse HCC model [101]. Additionally, NEMO deletion was found to induce hepatitis, fibrosis, and liver tumorigenesis [102]. The elimination of NF-κB activity in hepatocytes was shown to promote inflammatory cytokine expression and increase tumor formation in animals tested, indicating the vital role that NF-κB plays in suppressing tumor formation and growth [102]. Interestingly, the activation of IKKa has been found to mediate tumor suppression in human squamous cell carcinomas of the skin, lungs, and head and neck [15,16,103–106].

c-Jun N-terminal kinase (JNK) is a kinase that is responsible for the phosphorylation of proteins involved in both apoptotic and anti-apoptotic activity in cancer cells. The prolonged activation of JNK gives rise to the characteristic uncontrolled proliferation often observed in tumor cells [107,108]. Studies have shown that transient transfection of the kinase-mutated IKKB into human bronchial epithelial cells resulted in enhanced JNK activation following IKKB-NF-κB inhibition. Reactive oxygen species (ROS) have been suggested to play an important role in TNFα or arsenic-induced JNK activation in cells, during which the NF-κB pathway may be inhibited. NF-κB activation has therefore been suggested to be crucial in preventing cells from suffering from oxidative stress through curbing ROS generation and thereby preventing JNK activation [109,110].

7. Inhibitors of NF-κB Function and Selected Pharmacological Strategies to Block NF-κB Function

A plethora of compounds consisting of small molecules, biologics, inhibitory peptides, and many other different types of bioactive molecules have been identified as inhibitors of NF-κB and categorized into different groups based on the stage of NF-κB activation at which they exert their inhibitory effects [111–114]. These groups include agents that act at various steps of NF-κB signaling at (i) upstream of IKK, (ii) directly affecting the IKK complex or IκB phosphorylation, (iii) ubiquitination or proteasomal degradation of IκB, (iv) nuclear translocation of NF-κB, (v) NF-κB DNA binding, and (vi) NF-κB-directed gene transactivation.

7.1. Inhibitors That Act Upstream of the IKK Complex

Since the IKK complex is usually involved in the initial stages of the pathways leading to NF-κB activation, one viable strategy for inhibition NF-κB activation would be to block a signal upstream of IKK to prevent it from activating the IKK complex [2,81,114].

TNF-Rs comprise a family of 29 structurally-related receptors, which are bound by 19 ligands of the TNF superfamily [115–119]. The usage of anti-TNF antibodies or agents that block the TNF-R, such as infliximab and etanercept, can inhibit TNF-induced NF-κB activation and can have benefits in various autoimmune diseases [115,120,121]. Infliximab, a chimeric anti-TNFα antibody, is capable of inhibiting TNF-induced inflammation through binding to membrane TNF and preventing TNF binding to its receptors [115,122,123]. Etanercept, a TNF-receptor: Ig fusion protein is similarly capable of blocking the TNF’s cytotoxicity and ability to induce inflammation through binding to human TNF [115]. However, patients treated with these drugs often experience significant side effects, including fevers, hypotension, and nausea [115,124–126]. The risks associated with the use of anti-TNF antibodies include the possibility of the development of anti-drug antibodies that can result in the loss of clinical response as well as other adverse drug reactions, including acute hypersensitivity [127–129]. However, it has been found that co-administration of immune suppressants, such as methotrexate,
generally reduces the incidence of anti-drug antibodies [130]. The careful monitoring of disease progression, along with anti-drug antibody monitoring is therefore crucial in ensuring the safe use of anti-TNF antibodies [131].

Bruton’s tyrosine kinase (BTK) protein is essential for B proliferation in response to B cell antigen receptor (BCR) stimulation. BCR exposure can lead to the activation of NF-κB which, in turn, can regulate various genes controlling B cell growth. In both transformed and primary B cells, the absence of BTK severely limited B cell antigen receptor (BCR)-induced NF-κB activation. The loss of BTK in cells has also been associated with defects in the nuclear translocation of RelA and c-Rel, both crucial transactivating subunits of NF-κB in B cells [132–134]. For example, Ibrutinib (PCI-32765) binds to the cysteine residue 481 in the BTK active site, thereby inhibiting BTK phosphorylation on tyrosine 223 and preventing BTK activity [135].

While cases of primary and secondary resistance towards ibrutinib in B-cell malignancies have emerged, and mutations within BTK have been observed to affect the efficacy of the drug, there have been alternative mechanisms identified that provide the option to bypass BTK entirely, thus providing alternative options for other targeted agents [136]. The gene encoding the adaptor protein MYD88, which is responsible for the activation of toll-like receptors (TLRs), is frequently observed to be mutated in hematological malignancies where it can induce constitutive NF-κB activation, thus making TLR signaling a viable target for therapeutic efficacy [137,138].

IMO-8400, an antisense oligonucleotide TLR inhibitor, has been shown to specifically target TLR7, TLR8, and TLR in preclinical studies and is effective in reducing the size of Waldenstrom macroglobulinemia (WM) and diffuse large B-cell lymphoma (DLBCL) xenografts, driven by gain-of-function MYD88 mutations [138]. A phase I/II trial of IMO-8400 is ongoing in patients with WM and DLBCL, and second generation TLR 7/TLR 8/TLR9 inhibitors are currently in development. Interestingly, IMO-8400 was also found to exhibit clinical efficacy in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis [139].

7.2. IKK Inhibitors

As the IKK complex plays a crucial role in signal integration for NF-κB activation pathways, it has attracted much interest and research into compounds that are able to block IκB phosphorylation and, hence, also prevent ubiquitination of IκBα and its further degradation [25,140,141]. However, while many inhibitors have been developed, few have managed to enter into clinical trials and none have been clinically approved [141,142]. However, it must also be noted that while the targeting IKK2 holds promise as a likely anti-inflammatory therapy, it was found that pharmacological IKK2 inhibition can also result in increased endotoxin susceptibility that is associated with increased levels of IL-1β as a result of increased pro-IL-1β secretion by macrophages and neutrophils upon bacterial infections, thereby causing overt systemic inflammation and lethality in mice [143].

Although numerous agents have been identified to be involved in the inhibition of NF-κB activation at the IKK step, the exact mechanism through which all these agents inhibit IKK is still not fully understood [25,141]. Of the few IKKα/β inhibitors that have been investigated, the mechanisms of action identified can be classified into three categories: adenosine triphosphate (ATP) analogues, which show some specificity for interacting with IKK; compounds that have allosteric effects on IKK structure; and agents interfering with the kinase activation loops [25,144–146].

ATP analogs include natural products such as β-carboline and synthetic compounds such as SC-839, which has an approximately 200-fold preference for IKKB compared to IKKa [147,148]. BMS-345541 is a synthetic compound capable of exerting an allosteric effect on the IKK structure and has been observed to inhibit ATP binding to IKKa as well as inhibiting the expression of cytokines including TNFα, IL-1β, -8, and -6 [25,145,146,149,150]. In addition, various natural products including curcumin, pinitol, honokiol, mangiferin, etc. have also been reported to modulate IKK activation in diverse tumor cell lines [141].
The interaction between the C-terminus NEMO binding domain of the IKK complex and NEMO is a crucial step in the activation of the IKK complex, hence, it is an attractive target for the prevention of IKK complex formation and subsequent NF-κB activation. Phenothiazine 22 and its related analogs (22.2, 22.4, and 22.10) have been identified as potential drugs to be used to inhibit NF-κB activation due to their ability to reduce nitrite production and inducible nitric oxide synthase mRNA expression when administered to murine macrophages stimulated with lipopolysaccharide. These effects have been observed to be accompanied by NF-κB inhibition as well as the decreased expression of phosphorylated IKKβ, IkBα, and NF-κB/p65 [151].

Dominant-negative forms of IKKα and IKKβ are also able to function as inhibitors to modulate IKK activation as they are capable of showing stimulus-dependent inhibition due to their role in both the canonical and non-canonical pathways [25,145,152–154].

7.3. Proteasomal Degradation of IκBα

Since the ubiquitination of IκB by the SCF-B-TrCP ubiquitin ligase complex and the subsequent degradation by the 26S proteasome is a crucial step in the NF-κB activation pathways, preventing the degradation of IκBα is a potential method of treatment to prevent NF-κB activation [13,14,141,155,156]. Among IκB ubiquitination blockers, the virulence factor YopJ can act as a promiscuous deubiquitinating enzyme and is able to negatively regulate signaling by removing ubiquitin moieties from critical proteins such as the TNF receptor-associated factor (TRAF)2, TRAF6, and IκBα [157].

Peptide boronic acids named PS-262, PS-273, PS-341, and PS-402 were originally used as inhibitors of serine proteases but were noted to act as proteasome inhibitors by blocking the chymotrypsin-like site in the 20S subunit core and to be more potent than their aldehyde analogs [158–160]. Bortezomib is one such inhibitor that has been shown to prevent tumor growth and promote cell apoptosis in numerous cancers [141,161–164]. Carfilzomib, a tetrapeptide ketoepoxide, has also been demonstrated to induce apoptosis in chronic lymphocytic leukemia patient cells in the presence of human serum [165]. However, reports have revealed that bortezomib is also capable of downregulating IκBα expression and promoting NF-κB activation via the canonical pathway in multiple myeloma cell lines and primary tumor cells from patients [166]. Similarly, proteasome inhibitors MG-115, MG-132, and lactacystin were also shown to promote NF-κB activation in cells through an increase in IKK activation and IκBα degradation, further highlighting how the use of proteasome inhibitors to prevent NF-κB may not necessarily block NF-κB activation in cancer cells [141,167].

7.4. NF-κB DNA Binding

One method for inhibiting NF-κB activation through the prevention of NF-κB DNA binding involves the use of small peptides that are able to permeate the cell membrane to block NF-κB nuclear translocation [2,81,114,168,169]. SN-50, a forty-one-residue synthetic peptide containing a hydrophobic membrane-translocating region and the nuclear localization sequence of NF-κB p50, has been shown to inhibit NF-κB activation at high concentrations through the saturation of the transport machinery responsible for importing p50-containing dimers into the nucleus [145,146,170]. However, despite its ability to inhibit NF-κB activation, the high peptide concentration required to achieve the desired inhibition, along with the non-specific nature of the inhibition during which other unrelated transcription factors are similarly affected, limits the ability for the peptide inhibitor to be used in treatment [2,81,114,171]. A cell-permeable peptide containing the NF-κB nuclear localization sequence (NLS) was found to specifically block the importin α-mediated nuclear import of NF-κB, thereby reducing the effects of inflammation in vascular smooth muscle cells and macrophages. Plaques from NLS-treated mice were also found to contain fewer macrophages of the pro-inflammatory M1 subtype than those from respective untreated controls, thereby indicating the potential of NLS to target NF-κB nuclear translocation and prevent inflammation [172].

Numerous sesquiterpene lactones (SLs) have been found to contribute to the inhibition of NF-κB by preventing inflammation and blocking RelA-containing NF-κB dimers from binding to DNA by
interacting with C38 within RelA’s DNA-binding loop 1 [145,146]. While it has been suggested that SLs exert their inhibitory effect through the degradation of IκB, when okadaic acid-stimulated cells were treated with helenalin, no IκB degradation or NF-κB nuclear translocation was observed and this SL was found to selectively alkylate the p65 subunit of NF-κB, suggesting that SLs may possibly exert their effects through directly modifying NF-κB [173].

Decoy oligodeoxynucleotides (ODNs) are also capable of preventing NF-κB DNA binding through binding to specific genomic promoters with their κB sites, thereby preventing NF-κB dimer binding [2,81,114,174–176]. Treatment using ODNs has been reported to be successful in numerous animal models of inflammation and cancer, and can be pursued further in clinical settings [2,81,114,146,177–179].

7.5. Non-Steroidal Anti-Inflammatory Drugs and Antioxidants

Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin have been shown to suppress NF-κB, which controls the expression of genes such as cyclooxygenase (COX)-2 and cyclin D1, leading to the inhibition of proliferation of tumor cells [114,180]. Interestingly, NSAIDs have been found to differ in their ability to suppress NF-κB activation, with aspirin and ibuprofen being the least potent and with resveratrol, curcumin, celecoxib, and tamoxifen being the most potent amongst the agents investigated [181]. There is also compelling evidence to suggest that c-Src may be an upstream mediator of aspirin/NSAID effects on NF-κB signaling and apoptosis in colorectal cancer cells [182]. However, it was also found that hepatocytes are not sensitive to NF-κB inhibition by NSAIDs and that these drugs, especially the COX-2 selective inhibitors, do not survival [183]. In another study, it was reported that a new H2S-releasing derivative of naproxen, ATB-346 [2-(6-methoxynapthalen-2-yl)-propionic acid 4-thiocarbamoyl phenyl ester] can abrogate proliferation and induce apoptosis via the negative regulation of NF-κB activation in human melanoma cells [184]. Moreover, the co-administration of three different NSAIDs (celecoxib, etoricoxib, and diclofenac) was found to significantly abrogate the development of the 1,2-dimethylhydrazine dihydrochloride-induced colorectal cancer via the suppression of the NF-κB activation cascade [185].

7.6. Gene Therapy Approaches

Gene therapy involves the use of therapeutic vectors to target NF-κB via a long-term approach and has been heavily researched as a potential treatment for cancer. These therapeutic vectors can be administrated either systemically or locally at the site of inflammation, though the latter approach is deemed as a safer one due to the reduced risks of toxic side-effects as well as its ability to maintain constant therapeutic levels in the target tissue [77,186,187].

Viral-mediated gene transfer is an effective method for administering therapeutic proteins in vivo, with the type of vector being chosen based on cell type and nature of the disease in order to maximize the therapeutic effects [188–190]. Adenoviral vectors used in the intra-articular gene transfer of a dominant-negative adenoviral IKKβ construct (Ad.IKKBdn) was shown to significantly ameliorate the severity of adjuvant arthritis in mice and was accompanied by a significant decrease in NF-κB DNA expression in the joints of the treated animals [191]. The adenovirus vector expressing the dominant negative mutant of IKKβ was also found to be a viable anti-cancer therapy and sensitized human prostate carcinoma cells, neuroblastoma cells, and lung cancer cells to TRAIL- or TNF-induced apoptosis, suggesting that targeting NF-κB at the level of IKKβ through the use of adenoviral vectors appears promising [192–194].

Recombinant adenoviruses (Ads) are effective vectors for gene transfer due to their ability to infect numerous different types of tissues and cell types without needing a replicating target cell. Most recombinant Ads have deletions of early region 3 (E3) genes, allowing more space for insertion of the transgene. The E3 region of Ads has been shown to inhibit the activation of NF-κB induced by TNF-α and IL-1, as well as preventing NF-κB from entering the nucleus and preventing the activation of IKK [195].
Decoy ODNs are short synthetic fragments of DNA or RNA, mimicking complementary sequences of nucleic acids or transcription factors, and thus preventing the transcription factors from binding to the target gene promoter region. They have been shown to suppress NF-κB activation as well as mRNA expression of TNF-α, IFN-γ, and ICAM-1 in liver grafts, with a significantly lower hepatic NF-κB DNA binding activity [196]. However, the therapeutic use of ODNs is strongly hampered by their low bioavailability and short half-life [77,186,187,197]. While different strategies involving chemical modifications of the nucleic acid backbone and use of delivery systems have been investigated to overcome the pharmacokinetic drawbacks of ODNs, many chemical modifications have met with unsuccessful results [186,198].

RNA interference (RNAi) is the specific suppression of genes by short, double-stranded RNA. Small interfering RNA (siRNA) has been shown to be capable of inhibiting NF-κB activation through decreasing p65 and IKK1-IKK2 expression [199,200]. The transfection of siRNA targeting p65 was also shown to significantly inhibit NF-κB activation, induce cell cycle arrest, cell death, and sensitize head and neck squamous cell carcinoma cells when combined with histone deacetylase inhibitors [201]. However, it must also be noted that vector-based, sustained high-level delivery of siRNAs can lead to dose-dependent liver injury and even death in mouse models [202].

8. Conclusions

NF-κB has gained much recognition for its role in cancer and as one of the most important pro-inflammatory transcription factors. Although extensive research successfully supports and demonstrates the efficacy of NF-κB inhibitors in adjuvant therapy, the potential undesirable side-effects of prolonged NF-κB inhibition must also be taken into account when proposing novel treatment plans. NF-κB inhibitors should also always be tested and used with caution due to the context-dependent nature of NF-κB function in cells along with its tumor promoting and pro-survival abilities. While NSAIDs, corticosteroids, and many other drugs are currently being used for treating inflammatory conditions and cancers, it should be noted that these drugs often lack specificity for inhibiting NF-κB activity and consequently require relatively high concentrations. Thus, the identification of novel approaches to target this master transcription factor is still needed.

Author Contributions: Conceived the project and wrote the manuscript: P.Y.R., L.F., S.M.K.; conceived the project, wrote and edited the manuscript: G.S., F.A., V.T.

Funding: This work was supported by NUHS Basic seed grant (T1-BSRG 2015-02) and Ministry of Education Tier 1 grant to G.S.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sethi, G.; Sung, B.; Aggarwal, B.B. Nuclear factor-kappaB activation: From bench to bedside. Expe. Biol. Med. 2008, 233, 21–31. [CrossRef] [PubMed]
2. Sethi, G.; Tergaonkar, V. Potential pharmacological control of the NF-κB pathway. Trends Pharmacol. Sci. 2009, 30, 313–321. [CrossRef] [PubMed]
3. Todoric, J.; Antonucci, L.; Karin, M. Targeting inflammation in cancer prevention and therapy. Cancer Prev. Res. 2016, 9, 895–905. [CrossRef] [PubMed]
4. Taniguchi, K.; Karin, M. NF-κB, inflammation, immunity and cancer: Coming of age. Nat. Rev. Immunol. 2018, 18, 309–324. [CrossRef] [PubMed]
5. Shalapour, S.; Karin, M. Immunity, inflammation, and cancer: An eternal fight between good and evil. J. Clin. Investig. 2015, 125, 3347–3355. [CrossRef] [PubMed]
6. Li, F.; Zhang, J.; Arfuso, F.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Kumar, A.P.; Ahn, K.S.; Sethi, G. NF-κB in cancer therapy. Arch. Toxicol. 2015, 89, 711–731. [CrossRef] [PubMed]
7. Shin, E.M.; Hay, H.S.; Lee, M.H.; Goh, J.N.; Tan, T.Z.; Sen, Y.P.; Lim, S.W.; Yousef, E.M.; Ong, H.T.; Thike, A.A.; et al. Dead-box helicase dp103 defines metastatic potential of human breast cancers. J. Clin. Investig. 2014, 124, 3807–3824. [CrossRef] [PubMed]
8. Tergaonkar, V. NF-κB pathway: A good signaling paradigm and therapeutic target. *Int. J. Biochem. Cell Biol.* **2006**, *38*, 1647–1653. [CrossRef] [PubMed]

9. Maubach, G.; Schmadicke, A.C.; Naumann, M. Nemo links nuclear factor-kappab to human diseases. *Trends Mol. Med.* **2017**, *23*, 1138–1155. [CrossRef] [PubMed]

10. Pires, B.R.B.; Silva, R.; Ferreira, G.M.; Abdelhay, E. NF-κB: Two sides of the same coin. *Genes* **2018**, *9*, 24. [CrossRef] [PubMed]

11. Zhang, Q.; Lenardo, M.J.; Baltimore, D. 30 years of NF-κB. *Cell* **2017**, *168*, 37–57. [CrossRef] [PubMed]

12. Colombo, F.; Zambrano, S.; Agresti, A. NF-κB, the importance of being dynamic: Role and insights in cancer. *Biomedicines* **2018**, *6*, 45. [CrossRef] [PubMed]

13. Perkins, N.D. Integrating cell-signalling pathways with NF-κB. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 49–62. [CrossRef] [PubMed]

14. Scheidereit, C. Ikappab kinase complexes: Gateways to NF-κB activation and transcription. *Oncogene* **2006**, *25*, 6685–6705. [CrossRef] [PubMed]

15. Sethi, G.; Shanmugam, M.K.; Ramachandran, L.; Kumar, A.P.; Tergaonkar, V. Multifaceted link between cancer and inflammation. *Biosci. Rep.* **2012**, *32*, 1–15. [CrossRef] [PubMed]

16. Chai, E.Z.; Siveen, K.S.; Shanmugam, M.K.; Arfuso, F.; Sethi, G. Analysis of the intricate relationship between chronic inflammation and cancer. *Biochem. J.* **2015**, *468*, 1–15. [CrossRef] [PubMed]

17. Vallabhapurapu, S.; Karin, M. Regulation and function of NF-κB transcription factors in the immune system. *Annu. Rev. Immunol.* **2009**, *27*, 693–733. [CrossRef] [PubMed]

18. Shen, H.M.; Tergaonkar, V. NF-κB signaling in carcinogenesis and as a potential molecular target for cancer therapy. *Apoptosis* **2009**, *14*, 348–363. [CrossRef] [PubMed]

19. Rogovskii, V.S. The linkage between inflammation and immune tolerance: Interfering with inflammation in cancer. *Curr. Cancer Drug Targets* **2017**, *17*, 325–332. [CrossRef] [PubMed]

20. Sun, S.C. The non-canonical NF-κB pathway in immunity and inflammation. *Nat. Rev. Immunol.* **2017**, *17*, 545–558. [CrossRef] [PubMed]

21. Chen, L.F.; Greene, W.C. Shaping the nuclear action of NF-κB. *Nat. Rev. Mol. Cell Biol.* **2004**, *5*, 392–401. [CrossRef] [PubMed]

22. Derudder, E.; Dejardin, E.; Pritchard, L.L.; Green, D.R.; Korner, M.; Baud, V. Relb/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotixin-beta receptor activation: Critical roles for p100. *J. Biol. Chem.* **2003**, *278*, 23278–23284. [CrossRef] [PubMed]

23. Sokolova, O.; Naumann, M. NF-κB signaling in gastric cancer. *Toxins* **2017**, *9*, 119. [CrossRef] [PubMed]

24. Perkins, N.D.; Gilmore, T.D. Good cop, bad cop: The different faces of NF-κB. *Cell Death Differ.* **2006**, *13*, 759–772. [CrossRef] [PubMed]

25. Durand, J.K.; Baldwin, A.S. Targeting ikk and NF-κB for therapy. *Adv. Protein Chem. Struct. Biol.* **2017**, *107*, 77–115. [CrossRef] [PubMed]

26. Anto, R.J.; Mukhopadhyay, A.; Shishodia, S.; Gairola, C.G.; Aggarwal, B.B. Cigarette smoke condensate activates nuclear transcription factor-kappab through phosphorylation and degradation of IkBα: Correlation with induction of cyclooxygenase-2. *Carcinogenesis* **2002**, *23*, 1511–1518. [CrossRef] [PubMed]

27. Mandrekar, P.; Catalano, D.; Szabo, G. Alcohol-induced regulation of nuclear regulatory factor-kappa beta in human monocytes. *Alcohol Clin. Exp. Res.* **1997**, *21*, 988–994. [PubMed]

28. O’Dea, E.L.; Kearns, J.D.; Hoffmann, A. Uv as an amplifier rather than inducer of NF-κB activity. *Mol. Cell Biol.* **2008**, *30*, 632–641. [CrossRef] [PubMed]

29. DeLuca, C.; Roullston, A.; Koromillas, A.; Wainberg, M.A.; Hiscott, J. Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-κB/rel pathway via enhanced IkBα degradation. *J. Virol.* **1996**, *70*, 5183–5193. [PubMed]

30. Meyer, M.; Caselmann, W.H.; Schluter, V.; Schreck, R.; Hofschneider, P.H.; Baeuerle, P.A. Hepatitis b virus transactivator mhbst: Activation of NF-κB, selective inhibition by antioxidants and integral membrane localization. *EMBO J.* **1992**, *11*, 2991–3001. [PubMed]

31. You, L.R.; Chen, C.M.; Lee, Y.H. Hepatitis c virus core protein enhances NF-κB signal pathway triggering by lymphotixin-beta receptor ligand and tumor necrosis factor alpha. *J. Virol.* **1999**, *73*, 1672–1681. [PubMed]

32. Munn, L.L. Cancer and inflammation. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **2017**, *9*, e1370. [CrossRef] [PubMed]
33. Sethi, G.; Ahn, K.S.; Chaturvedi, M.M.; Aggarwal, B.B. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IκBα kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IκBα. *Oncogene* **2007**, *26*, 7324–7332. [CrossRef] [PubMed]

34. Campbell, K.J.; O’Shea, J.M.; Perkins, N.D. Differential regulation of NF-κB activation and function by topoisomerase II inhibitors. *BMC Cancer* **2006**, *6*, 101. [CrossRef] [PubMed]

35. Li, F.; Sethi, G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. *Biochim. Biophys. Acta* **2010**, *1805*, 167–180. [CrossRef] [PubMed]

36. Siveen, K.S.; Mustafa, N.; Li, F.; Kannaiyan, R.; Ahn, K.S.; Kumar, A.P.; Chng, W.J.; Sethi, G. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. *Oncotarget* **2014**, *5*, 634–648. [CrossRef] [PubMed]

37. Li, F.; Shanmugam, M.K.; Siveen, K.S.; Wang, F.; Ong, T.H.; Loo, S.Y.; Swamy, M.M.; Mandal, S.; Kumar, A.P.; Goh, B.C.; et al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. *Oncotarget* **2015**, *6*, 5147–5163. [CrossRef] [PubMed]

38. Piret, B.; Piette, J. Topoisomerase poisons activate the transcription factor NF-κB in ACH-2 and CEM cells. *Nucleic Acids Res.* **1996**, *24*, 4242–4248. [CrossRef] [PubMed]

39. Bottero, V.; Busuttil, V.; Loubat, A.; Magne, N.; Fischel, J.L.; Milano, G.; Peyron, J.F. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in Hela human carcinoma cells. *Cancer Res.* **2001**, *61*, 7785–7791. [PubMed]

40. Andriollo, M.; Favier, A.; Guiraud, P. Adriamycin activates NF-κB in human lung carcinoma cells by IκBα degradation. *Arch. Biochem. Biophys.* **2003**, *413*, 75–82. [CrossRef]

41. Baumann, P.; Mandl-Weber, S.; Oduncu, F.; Schmidmaier, R. Alkylating agents induce activation of NF-κB in multiple myeloma cells. *Leuk. Res.* **2008**, *32*, 1144–1147. [CrossRef] [PubMed]

42. Tergaonkar, V.; Pando, M.; Vafa, O.; Wahl, G.; Verma, I. PS3 stabilization is decreased upon NF-κB activation: A role for NF-κB in acquisition of resistance to chemotherapy. *Cancer Cell* **2002**, *1*, 493–503. [CrossRef]

43. Tergaonkar, V.; Bottero, V.; Ikawa, M.; Li, Q.; Verma, I.M. IκBα/p65 kinase-independent IκBα degradation pathway: Functional NF-κB activity and implications for cancer therapy. *Mol. Cell. Biol.* **2003**, *23*, 8070–8083. [CrossRef] [PubMed]

44. Liang, L.; Fan, Y.; Cheng, J.; Cheng, D.; Zhao, Y.; Cao, B.; Ma, L.; An, L.; Jia, W.; Su, X.; et al. Tak1 ubiquitination regulates doxorubicin-induced NF-κB activation. *Cell. Signal.* **2013**, *25*, 247–254. [CrossRef] [PubMed]

45. Ho, W.C.; Dickson, K.M.; Barker, P.A. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. *Cancer Res.* **2005**, *65*, 4273–4281. [CrossRef] [PubMed]

46. Das, K.C.; White, C.W. Activation of NF-κB by antineoplastic agents. Role of protein kinase C. *J. Biol. Chem.* **1997**, *272*, 14914–14920. [CrossRef] [PubMed]

47. Brach, M.A.; Hass, R.; Sherman, M.L.; Gunji, H.; Weichselbaum, R.; Kufe, D. Ionizing radiation induces expression and binding activity of the nuclear factor kappaB b. *J. Clin. Investig.* **1991**, *88*, 691–695. [CrossRef] [PubMed]

48. Basu, S.; Rosenzweig, K.R.; Youmell, M.; Price, B.D. The DNA-dependent protein kinase participates in the activation of NF-kB following DNA damage. *Biochem. Biophys. Res. Commun.* **1998**, *247*, 79–83. [CrossRef] [PubMed]

49. Lee, S.J.; Dimtchev, A.; Lavin, M.F.; Dritschilo, A.; Jung, M. A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κB. *Oncogene* **1998**, *17*, 1821–1826. [CrossRef] [PubMed]

50. Zhou, D.; Brown, S.A.; Yu, T.; Chen, G.; Barve, S.; Kang, B.C.; Thompson, J.S. A high dose of ionizing radiation induces tissue-specific activation of nuclear factor-kappab in vivo. *Radiat. Res.* **1999**, *151*, 703–709. [CrossRef] [PubMed]

51. Li, N.; Karin, M. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 13012–13017. [CrossRef] [PubMed]

52. Chen, X.; Shen, B.; Xia, L.; Khaletzkiy, A.; Chu, D.; Wong, J.Y.; Li, J.J. Activation of nuclear factor kappab in radioresistance of tp53-inactive human keratinocytes. *Cancer Res.* **2002**, *62*, 1213–1221. [PubMed]

53. Criswell, T.; Leskov, K.; Miyamoto, S.; Luo, G.; Boothman, D.A. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. *Oncogene* **2003**, *22*, 5813–5827. [CrossRef] [PubMed]
54. Rodel, F.; Hantschel, M.; Hildebrandt, G.; Schultz-Mosgau, S.; Rodel, C.; Herrmann, M.; Sauer, R.; Voll, R.E. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa b (NF-kB) in EA.hy.926 endothelial cells after low-dose X-irradiation. *Int. J. Radiat. Biol.* 2004, 80, 115–123. [CrossRef] [PubMed]

55. Rithidech, K.N.; Tungtai, M.; Arbabi, E.; Simon, S.R. Activation of NF-kB in bone marrow cells of balb/cj mice following exposure in vivo to low doses of 137Cs gamma-rays. *Radiat. Environ. Biophys.* 2005, 44, 139–143. [CrossRef] [PubMed]

56. Ahmed, K.M.; Dong, S.; Fan, M.; Li, J.J. Nuclear factor-kappab p65 inhibits mitogen-activated protein kinase signaling pathway in radiosensitive breast cancer cells. *Mol. Cancer Res.* 2006, 4, 945–955. [CrossRef] [PubMed]

57. Lewis, D.A.; Spandau, D.F. Uvb activation of NF-kB in normal human keratinocytes occurs via a unique mechanism. *Arch. Dermatol. Res.* 2007, 299, 93–101. [CrossRef] [PubMed]

58. Laszlo, C.F.; Wu, S. Mechanism of uv-induced IxBa-independent activation of NF-kB. *Photochem. Photobiol.* 2008, 84, 1564–1568. [CrossRef] [PubMed]

59. Cao, N.; Li, S.; Wang, Z.; Ahmed, K.M.; Degnan, M.E.; Fan, M.; Dynlacht, J.R.; Li, J.J. NF-kB-mediated HER2 overexpression in radiation-adaptive resistance. *Radiat. Res.* 2009, 171, 9–21. [CrossRef] [PubMed]

60. Veuger, S.J.; Hunter, J.E.; Durkacz, B.W. Ionizing radiation-induced NF-kB activation requires PARP-1 function to confer radioresistance. *Oncogene* 2009, 28, 832–842. [CrossRef] [PubMed]

61. Pordanjani, S.M.; Hosseiminejeh, S.J. The role of nf-kb inhibitors in cell response to radiation. *Curr. Med. Chem.* 2016, 23, 3951–3963. [CrossRef] [PubMed]

62. Sahijdak, W.M.; Yang, C.R.; Zuckerman, J.S.; Meyers, M.; Boothman, D.A. Alterations in transcription factor binding in radiosensitive human melanoma cells after ionizing radiation. *Radiat. Res.* 1994, 138, S47–S51. [CrossRef] [PubMed]

63. Ashburner, B.P.; Shackelford, R.E.; Baldwin, A.S., Jr; Paules, R.S. Lack of involvement of ataxia telangiectasia mutated (ATM) in regulation of nuclear factor-kappab (NF-kB) in human diploid fibroblasts. *Cancer Res.* 1999, 59, 5456–5460. [PubMed]

64. Li, N.; Banin, S.; Ouyang, H.; Li, G.C.; Courtois, G.; Shiloh, Y.; Karin, M.; Rotman, G. ATM is required for IxB kinase (IKK) activation in response to DNA double strand breaks. *J. Biol. Chem.* 2001, 276, 8898–8903. [CrossRef] [PubMed]

65. Huang, T.T.; Wuerzberger-Davis, S.M.; Seufzer, B.J.; Shumway, S.D.; Kurama, T.; Boothman, D.A.; Miyamoto, S. NF-kB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. *J. Biol. Chem.* 2000, 275, 9501–9509. [CrossRef] [PubMed]

66. Jung, M.; Kondratyev, A.; Lee, S.A.; Dimtchev, A.; Dritschilo, A. ATM gene product phosphorylates I kappa B-alpha. *Cancer Res.* 1997, 57, 24–27. [PubMed]

67. Raju, U.; Gumin, G.J.; Noel, F.; Tofilon, P.J. IxBa degradation is not a requirement for the x-ray-induced activation of nuclear factor kappab in normal rat astrocytes and human brain tumour cells. *Int. J. Radiat. Biol.* 1998, 74, 617–624. [CrossRef] [PubMed]

68. Curry, H.A.; Clemens, R.A.; Shah, S.; Bradbury, C.M.; Botero, A.; Goswami, P.; Gius, D. Heat shock inhibits radiation-induced activation of NF-kB via inhibition of I-kB kinase. *J. Biol. Chem.* 1999, 274, 23061–23067. [CrossRef] [PubMed]

69. Miyakoshi, J.; Yagi, K. Inhibition of I kB-α phosphorylation at serine and tyrosine acts independently on sensitization to DNA damaging agents in human glioma cells. *Br. J. Cancer* 2000, 82, 28–33. [CrossRef] [PubMed]

70. Yakovlev, V.A.; Barani, I.J.; Rabender, C.S.; Black, S.M.; Leach, J.K.; Graves, P.R.; Kellogg, G.E.; Mikkelsen, R.B. Tyrosine nitration of IxBα: A novel mechanism for NF-kB activation. *Biochemistry* 2007, 46, 11671–11683. [CrossRef] [PubMed]

71. Campbell, K.J.; Chapman, N.R.; Perkins, N.D. UV stimulation induces nuclear factor κB (NF-κB) DNA-binding activity but not transcriptional activation. *Biochem. Soc. Trans.* 2001, 29, 688–691. [CrossRef] [PubMed]

72. Pikarsky, E.; Porat, R.M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.; Galun, E.; Ben-Neriah, Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. *Nature* 2004, 431, 461–466. [CrossRef] [PubMed]
73. Lawrence, T.; Gilroy, D.W.; Colville-Nash, P.R.; Willoughby, D.A. Possible new role for NF-κB in the resolution of inflammation. *Nat. Med.* **2001**, *7*, 1291–1297. [CrossRef] [PubMed]

74. Karin, M. Nuclear factor-kappab in cancer development and progression. *Nature* **2006**, *441*, 431–436. [CrossRef] [PubMed]

75. Dey, A.; Wong, E.; Kua, N.; Teo, H.L.; Tergaonkar, V.; Lane, D. Hexamethylene bisacetamide (HMBA) simultaneously targets akt and mapk pathway and represses NF-κB activity: Implications for cancer therapy. *Cell Cycle* **2008**, *7*, 3759–3767. [CrossRef] [PubMed]

76. Matthews, G.M.; de Matos Simoes, R.; Dhimolea, E.; Sheffer, M.; Gandolfi, S.; Dashevsky, O.; Sorrell, J.D.; Mitsuides, C.S. NF-κB dysregulation in multiple myeloma. *Semin. Cancer Biol.* **2016**, *39*, 68–76. [CrossRef] [PubMed]

77. Yu, L.; Li, L.; Medeiros, L.J.; Young, K.H. NF-κB promoter activation. *Nat. Cell Biol.* **2003**, *15*, 14402–14407. [CrossRef] [PubMed]

78. Wang, D.J.; Ratnam, N.M.; Byrd, J.C.; Guttridge, D.C. NF-κB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells. *Cell Rep.* **2014**, *9*, 90–103. [CrossRef] [PubMed]

79. Huang, S.; Pettaway, C.A.; Uehara, H.; Bucana, C.D.; Fidler, I.J. Blockade of NF-κB in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. *Oncogene* **2001**, *20*, 4188–4197. [CrossRef] [PubMed]

80. Xia, Y.; Shen, S.; Verma, I.M. NF-κB, an active player in human cancers. *Cancer Immunol. Res.* **2014**, *2*, 823–830. [CrossRef] [PubMed]

81. Panday, A.; Inda, M.E.; Bagam, P.; Sahoo, M.K.; Osorio, D.; Batra, S. Transcription factor NF-κB: An update on intervention strategies. *Arch. Immunol. Ther. Exp.* **2016**, *64*, 463–483. [CrossRef] [PubMed]

82. Li, Y.; Zhou, Q.L.; Sun, W.; Chandrasekharan, P.; Cheng, H.S.; Ying, Z.; Lakshmanan, M.; Raju, A.; Tenen, D.G.; Cheng, S.Y.; et al. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. *Nat. Cell Biol.* **2015**, *17*, 1327–1338. [CrossRef] [PubMed]

83. Tergaonkar, V. NF-κB drives tert promoter reactivation in cancer. *Cell Cycle* **2016**, *15*, 156–157. [CrossRef] [PubMed]

84. Li, Y.; Cheng, H.S.; Chng, W.J.; Tergaonkar, V. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 14402–14407. [CrossRef] [PubMed]

85. Khattar, E.; Kumar, P.; Liu, C.Y.; Akincilar, S.C.; Raju, A.; Lakshmanan, M.; Maury, J.J.; Qiang, Y.; Li, S.; Tan, E.Y.; et al. Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. *J. Clin. Invest.* **2016**, *126*, 4045–4060. [CrossRef] [PubMed]

86. Chen, B.J.; Zeng, S.; Xie, R.; Hu, C.J.; Wang, S.M.; Wu, Y.Y.; Xiao, Y.F.; Yang, S.M. Htet promotes gastric intestinal metaplasia by upregulating CDX2 via NF-κB signaling pathway. *Oncotarget* **2017**, *8*, 26969–26978. [CrossRef] [PubMed]

87. Fusella, F.; Secli, L.; Busso, E.; Krepelova, A.; Moiso, E.; Rocca, S.; Conti, L.; Annaratone, L.; Rubinetto, C.; Mello-Grand, M.; et al. The IKK/NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. *Blood Rev.* **2017**, *31*, 77–92. [CrossRef] [PubMed]

88. Manu, K.A.; Shanmugam, M.K.; Subramaniam, A.; Siveen, K.S.; Perumal, E.; Samy, R.P.; Bist, P.; Lim, L.H.; Kumar, A.P.; et al. Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma. *PLoS ONE* **2013**, *8*, e57015. [CrossRef] [PubMed]

89. Shanmugam, M.K.; Manu, K.A.; Ong, T.H.; Ramachandran, L.; Surana, R.; Bist, P.; Lim, L.H.; Kumar, A.P.; Hui, K.M.; Sethi, G. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. *Int. J. Cancer* **2011**, *129*, 1552–1563. [CrossRef] [PubMed]
92. Kang, Y.; Massague, J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004, 118, 277–279. [CrossRef] [PubMed]

93. Dai, X.; Ahn, K.S.; Wang, L.Z.; Kim, C.; Devisagammi, A.; Arfuso, F.; Um, J.Y.; Kumar, A.P.; Chang, Y.C.; Kumar, D.; et al. Ascoalomin enhances the sensitivity of doxorubicin leading to the reversal of epithelial-to-mesenchymal transition in hepatocellular carcinoma. Mol. Cancer Ther. 2016, 15, 2966–2976. [CrossRef] [PubMed]

94. Syn, N.; Wang, L.; Sethi, G.; Thiery, J.P.; Goh, B.C. Exosome-mediated metastasis: From epithelial-mesenchymal transition to escape from immunosurveillance. Trends Pharmacol. Sci. 2016, 37, 606–617. [CrossRef] [PubMed]

95. Tang, D.; Tao, D.; Fang, Y.; Deng, C.; Xu, Q.; Zhou, J. TNF-alpha promotes invasion and metastasis via NF-kB pathway in oral squamous cell carcinoma. Med. Sci. Monit. Basic Res. 2017, 23, 141–149. [CrossRef] [PubMed]

96. Waters, J.P.; Pober, J.S.; Bradley, J.R. Tumour necrosis factor and cancer. J. Pathol. 2013, 230, 241–248. [CrossRef] [PubMed]

97. Hwang, J.R.; Jo, K.; Lee, Y.; Sung, B.J.; Park, Y.W.; Lee, J.H. Upregulation of CD9 in ovarian cancer is related to the induction of TNF-alpha gene expression and constitutive NF-kB activation. Carcinogenesis 2012, 33, 77–83. [CrossRef] [PubMed]

98. Wu, Y.; Zhou, B.P. TNF-alpha/NF-kB/snafl pathway in cancer cell migration and invasion. Br. J. Cancer 2010, 102, 639–644. [CrossRef] [PubMed]

99. Collins, T.; Read, M.A.; Neish, A.S.; Whitley, M.Z.; Thanos, D.; Maniatis, T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers. FASEB J. 1995, 9, 899–909. [CrossRef] [PubMed]

100. Nguyen, D.X.; Bos, P.D.; Massague, J. Metastasis: From dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9, 274–284. [CrossRef] [PubMed]

101. Maeda, S.; Kamata, H.; Luo, J.L.; Leffert, H.; Karin, M. IKK couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121, 977–990. [CrossRef] [PubMed]

102. Luedde, T.; Beraza, N.; Kotsikoris, V.; van Loo, G.; Nenci, A.; De Vos, R.; Roskams, T.; Trautwein, C.; Pasparakis, M. Deletion of nemo/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11, 119–132. [CrossRef] [PubMed]

103. Chaturvedi, M.M.; Sung, B.; Yadav, V.R.; Kannappan, R.; Aggarwal, B.B. NF-kB addiction and its role in cancer: ‘One size does not fit all’. Oncogene 2011, 30, 1615–1630. [CrossRef] [PubMed]

104. Maeda, G.; Chiba, T.; Kawashiri, S.; Satoh, T.; Imai, K. Epigenetic inactivation of Ikappba Kinase-alpha in oral carcinomas and tumor progression. Clin. Cancer Res. 2007, 13, 5041–5047. [CrossRef] [PubMed]

105. Van Waes, C.; Yu, M.; Nottingham, L.; Karin, M. Inhibitor-kappab kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin. Cancer Res. 2007, 13, 4956–4959. [CrossRef] [PubMed]

106. Ting, A.T.; Bertrand, M.J.M. More to life than NF-kB in tnfr1 signaling. Trends Immunol. 2016, 37, 535–545. [CrossRef] [PubMed]

107. Kannaiyan, R.; Manu, K.A.; Chen, L.; Li, F.; Rajendran, P.; Subramaniam, A.; Lam, P.; Kumar, A.P.; Sethi, G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-jun n-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 2011, 16, 1028–1041. [CrossRef] [PubMed]

108. Dai, X.; Wang, L.; Devisagammi, A.; Looi, C.Y.; Karthikeyan, C.; Trivedi, P.; Chinnathambi, A.; Alharbi, S.A.; Arfuso, F.; Dharmarajan, A.; et al. A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. Oncotarget 2017, 8, 12631–12642. [CrossRef] [PubMed]

109. Chen, F.; Castranova, V. Nuclear factor-kappab, an unappreciated tumor suppressor. Cancer Res. 2007, 67, 11093–11098. [CrossRef] [PubMed]

110. Zhang, Y.; Chen, F. Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kB) and c-Jun NH2-terminal kinase (JNK). Cancer Res. 2004, 64, 1902–1905. [CrossRef] [PubMed]

111. Neelgundmath, M.; Dinesh, K.R.; Mohan, C.D.; Li, F.; Dai, X.; Siveen, K.S.; Paricharak, S.; Mason, D.J.; Fuchs, J.E.; Sethi, G.; et al. Novel synthetic coumarins that targets NF-kB in hepatocellular carcinoma. Bioorg. Med. Chem. Lett. 2015, 25, 893–897. [CrossRef] [PubMed]
112. Mohan, C.D.; Anilkumar, N.C.; Rangappa, S.; Shanmugam, M.K.; Mishra, S.; Chinnathambi, A.; Alharbi, S.A.; Bhattacharjee, A.; Sethi, G.; Kumar, A.P.; et al. Novel 1,3,4-oxadiazole induces anticancer activity by targeting NF-κB in hepatocellular carcinoma cells. *Front. Oncol.* **2018**, *8*, 42. [CrossRef] [PubMed]

113. Jain, H.; Dhingra, N.; Narsinghani, T.; Sharma, R. Insights into the mechanism of natural terpenoids as NF-κB inhibitors: An overview on their anticancer potential. *Exp. Oncol.* **2016**, *38*, 158–168. [PubMed]

114. De Castro Barbosa, M.L.; da Conceicao, R.A.; Fraga, A.G.M.; Camarinh, B.D.; de Carvalho Silva, G.C.; Lima, A.G.F.; Cardoso, E.A.; de Oliveira Freitas Lione, V. NF-κB signaling pathway inhibitors as anticancer drug candidates. *Anticancer Agents Med. Chem.* **2017**, *17*, 483–490. [CrossRef] [PubMed]

115. Sethi, G.; Sung, B.; Kunnunakkara, A.B.; Aggarwal, B.B. Targeting TNF for treatment of cancer and autoimmunity. *Adv. Exp. Med. Biol.* **2009**, *647*, 37–51. [CrossRef] [PubMed]

116. Keerthy, H.K.; Mohan, C.D.; Sivaraman Siveen, K.; Fuchs, J.E.; Rangappa, S.; Sundaram, M.S.; Li, F.; Girish, K.S.; Sethi, G.; Basappa; et al. Novel synthetic bismuths inhibit tumor necrosis factor-alpha in hepatocellular carcinoma in vitro and in vivo. *J. Biol. Chem.* **2014**, *289*, 31879–31890. [CrossRef]

117. Dai, X.; Zhang, J.; Arfuso, F.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Kumar, A.P.; Ahn, K.S.; Sethi, G. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. *Exp. Biol. Med.* **2015**, *240*, 760–773. [CrossRef] [PubMed]

118. Nirvanappa, A.C.; Mohan, C.D.; Rangappa, S.; Ananda, H.; Sukhorukov, A.Y.; Shanmugam, M.K.; Sundaram, M.S.; Nayaka, S.C.; Girish, K.S.; Chinnathambi, A.; et al. Novel synthetic oxazines target NF-κB in colon cancer in vitro and inflammatory bowel disease in vivo. *PLoS ONE* **2016**, *11*, e0163209. [CrossRef] [PubMed]

119. Ningegowda, R.; Shivananju, N.S.; Rajendran, P.; Basappa; Rangappa, K.S.; Chinnathambi, A.; Li, F.; Achar, R.R.; Shanmugam, M.K.; Bist, P.; et al. A novel 4,6-disubstituted-1,2,4-triazolo-1,3,4-thiadiazole derivative inhibits tumor cell invasion and potentiates the apoptotic effect of TNFalpha by abrogating NF-κB activation cascade. *Apoptosis* **2017**, *22*, 145–157. [CrossRef] [PubMed]

120. Song, X.Y.; Torphy, T.J.; Griswold, D.E.; Shealy, D. Coming of age: Anti-cytokine therapies. *Nat. Rev. Drug Discov.* **2013**, *12*, 147–168. [CrossRef] [PubMed]

121. Siegel, S.A.; Shealy, D.J.; Nakada, M.T.; Le, J.; Woulfe, D.S.; Probert, L.; Kollias, G.; Ghayeb, J.; Vilecek, J.; Daddona, P.E. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. *Cytokine* **1995**, *7*, 15–25. [CrossRef] [PubMed]

122. Scallon, B.J.; Moore, M.A.; Trinh, H.; Knight, D.M.; Ghayeb, J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. *Cytokine* **1995**, *7*, 251–259. [CrossRef] [PubMed]

123. Klareskog, L.; van der Heijde, D.; de Jager, J.P.; Gough, A.; Kalden, J.; Martin Mola, E.; Pavelka, K.; Sany, J.; Settas, L.; et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. *Lancet* **2004**, *363*, 675–681. [CrossRef]

124. Van der Heijde, D.; Klareskog, L.; Rodriguez-Valverde, V.; Codreanu, C.; Bolosiu, H.; Melo-Gomes, J.; Tornero-Molina, J.; Wajdula, J.; Pedersen, R.; Fatenejad, S. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the tempo study, a double-blind, randomized trial. *Arthritis Rheum.* **2006**, *54*, 1063–1074. [CrossRef] [PubMed]

125. Lethaby, A.; Lopez-Olivo, M.A.; Maxwell, L.; Burlés, A.; Tugwell, P.; Wells, G.A. Etanercept for the treatment of rheumatoid arthritis. *Cochrane Database Syst. Rev.* **2013**, *5*, CD004525. [CrossRef] [PubMed]

126. Van Schouwenburg, P.A.; van de Stadt, L.A.; de Jong, R.N.; van Buren, E.E.; Kruithof, S.; de Groot, E.; Hart, M.; van Ham, S.M.; Rispens, T.; Aarden, L.; et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. *Ann. Rheum. Dis.* **2013**, *72*, 104–109. [CrossRef] [PubMed]

127. Bhattacharjee, A.; Sethi, G.; Kumar, A.P.; et al. Novel 1,3,4-oxadiazole induces anticancer activity by targeting NF-κB in hepatocellular carcinoma cells. *Front. Oncol.* **2018**, *8*, 42. [CrossRef] [PubMed]

128. Nanda, K.S.; Cheifetz, A.S.; Moss, A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-analysis. *Am. J. Gastroenterol.* **2013**, *108*, 40–47. [CrossRef] [PubMed]
129. Steenholdt, C.; Svenson, M.; Bendtzen, K.; Thomsen, O.O.; Brynskov, J.; Ainsworth, M.A. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn’s disease. J. Crohns Colitis 2012, 6, 108–111. [CrossRef] [PubMed]

130. Carces, S.; Demengeot, J.; Benito-Garcia, E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann. Rheum. Dis. 2013, 72, 1947–1955. [CrossRef] [PubMed]

131. Sedger, L.M.; McDermott, M.F. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants—Past, present and future. Cytokine Growth Factor Rev. 2014, 25, 453–472. [CrossRef] [PubMed]

132. Petro, J.B.; Rahman, S.M.; Ballard, D.W.; Khan, W.N. Bruton’s tyrosine kinase is required for activation of IkB kinase and nuclear factor kappaB in response to B cell receptor engagement. J. Exp. Med. 2000, 191, 1745–1754. [CrossRef] [PubMed]

133. Baldwin, A.S., Jr. The NF-kB and IκB proteins: New discoveries and insights. Annu. Rev. Immunol. 1996, 14, 649–683. [CrossRef] [PubMed]

134. Verma, I.M.; Stevenson, J.K.; Schwarz, E.M.; Van Antwerp, D.; Miyamoto, S. Rel/NF-κB/IκB family: Intimate tales of association and dissociation. Genes Dev. 1995, 9, 2723–2735. [CrossRef] [PubMed]

135. Novero, A.; Ravella, P.M.; Chen, Y.; Dous, G.; Liu, D. Ibrutinib for B cell malignancies. Nat. Rev. Drug Discov. 2014, 3, 4. [CrossRef] [PubMed]

136. Zhang, S.Q.; Smith, S.M.; Zhang, S.Y.; Lynn Wang, Y. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-hodgkin lymphoma. Br. J. Haematol. 2015, 170, 445–456. [CrossRef] [PubMed]

137. Wang, J.Q.; Jeelall, Y.S.; Ferguson, L.L.; Horikawa, K. Toll-like receptors and cancer: MYD88 mutation and therapeutic strategy. Br. J. Haematol. 2014, 170, 621–632. [CrossRef] [PubMed]

138. Brenner, L.; Arbeit, R.D.; Sullivan, T. IMO-8400, an antagonist of toll-like receptors 7, 8, and 9, in development for genetically defined B-cell lymphomas: Safety and activity in phase 1 and phase 2 clinical trials. Blood 2014, 124, 3101.

139. Balak, D.M.; van Doorn, M.B.; Arbeit, R.D.; Rijneveld, R.; Klaassen, E.; Sullivan, T.; Brevard, J.; Thio, H.B.; Prens, E.P.; Burggraaf, J.; et al. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical pharmacological inhibition of IKKβ. Clin. Pharmacol. Ther. 2017, 174, 63–72. [CrossRef] [PubMed]

140. Basseres, D.S.; Baldwin, A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25, 6817–6830. [CrossRef] [PubMed]

141. Awasthee, N.; Rai, V.; Chava, S.; Nallasamy, P.; Kunnunakkara, A.B.; Bishayee, A.; Chauhan, S.C.; Challagundla, K.B.; Gupta, S.C. Targeting IκB kinases for cancer therapy. Semin. Cancer Biol. 2018, 25, 6817–6830. [CrossRef] [PubMed]

142. Begalli, F.; Bennett, J.; Capece, D.; Verzella, D.; D’Andrea, D.; Tornatore, L.; Franzoso, G. Unlocking the NF-κB conundrum: Embracing complexity to achieve specificity. Biomedicines 2017, 5, 50. [CrossRef] [PubMed]

143. Greten, F.R.; Arkan, M.C.; Bollrath, J.; Hsu, L.C.; Goode, J.; Miething, C.; Goktuna, S.I.; Neuenhahn, M.; Fierer, J.; Paxian, S.; et al. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 2007, 130, 918–931. [CrossRef] [PubMed]

144. Gamble, C.; McIntosh, K.; Scott, R.; Ho, K.H.; Plevin, R.; Paul, A. Inhibitory kappaB kinases as targets for pharmacological regulation. Br. J. Pharmacol. 2012, 165, 802–819. [CrossRef] [PubMed]

145. Gilmore, T.D.; Herscovitch, M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 2006, 25, 6887–6899. [CrossRef] [PubMed]

146. Gupta, S.C.; Sundaram, C.; Reuter, S.; Aggarwal, B.B. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta 2010, 1799, 775–787. [CrossRef] [PubMed]

147. Karin, M.; Yamamoto, Y.; Wang, Q.M. The IKK NF-κB system: A treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3, 17–26. [CrossRef] [PubMed]

148. Pande, V.; Ramos, M.J. NF-κB in human disease: Current inhibitors and prospects for de novo structure based design of inhibitors. Curr. Med. Chem. 2005, 12, 357–374. [CrossRef] [PubMed]

149. Pal, S.; Bhattacharjee, A.; Ali, A.; Mandal, N.C.; Mandal, S.C.; Pal, M. Chronic inflammation and cancer: Potential chemoprevention through nuclear factor kappaB and p53 mutual antagonism. J. Inflamm. 2014, 11, 23. [CrossRef] [PubMed]
169. Torgerson, T.R.; Colosia, A.D.; Donahue, J.P.; Lin, Y.Z.; Hawiger, J. Regulation of NF-κB, AP-1, NFAT, and STAT1 nuclear import in t lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-κB p50. *J. Immunol.* **1998**, *161*, 6084–6092. [PubMed]

170. Horie, R. Molecularly-targeted strategy and NF-κB in lymphoid malignancies. *J. Clin. Exp. Hematop.* **2013**, *53*, 185–195. [CrossRef] [PubMed]

171. Cunningham, M.D.; Cleaveland, J.; Nadler, S.G. An intracellular targeted NLS peptide inhibitor of karyopherin alpha: NF-κB interactions. *Biochem. Biophys. Res. Commun.* **2003**, *300*, 403–407. [CrossRef]

172. Mallavia, B.; Recio, C.; Oguiza, A.; Ortiz-Munoz, G.; Lazaro, I.; Lopez-Parra, V.; Lopez-Franco, O.; Schindler, S.; Depping, R.; Egidio, J.; et al. Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis. *Am. J. Pathol.* **2013**, *182*, 1910–1921. [CrossRef] [PubMed]

173. Lyss, G.; Knorre, A.; Schmidt, T.J.; Pahl, H.L.; Merfort, I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65. *J. Biol. Chem.* **1998**, *273*, 33508–33516. [CrossRef] [PubMed]

174. Morishita, R.; Sugimoto, T.; Aoki, M.; Kida, I.; Tomita, N.; Moriguchi, A.; Maeda, K.; Sawa, Y.; Kaneda, Y.; Higaki, J.; et al. In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. *Nat. Med.* **1997**, *3*, 894–899. [CrossRef] [PubMed]

175. Khaled, A.R.; Butfiloski, E.J.; Sobel, E.S.; Schifftenbauer, J. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-κB expression and lymphocyte function. *Clin. Immunol. Immunopathol.* **1998**, *86*, 170–179. [CrossRef] [PubMed]

176. Kupatt, C.; Wichels, R.; Deiss, M.; Molnar, A.; Lebherz, C.; Raake, P.; von Degenfeld, G.; Hahnel, D.; Boekstegers, P. Retrinfusion of NF-κB decoy oligonucleotide extends cardioprotection achieved by cd18 inhibition in a preclinical study of myocardial ischemia and reinfusion in pigs. *Gene Ther.* **2002**, *9*, 518–526. [CrossRef] [PubMed]

177. Tomita, N.; Oghara, T.; Morishita, R. Transcription factors as molecular targets: Molecular mechanisms of decoy ODN and their design. *Curr. Drug Targets* **2003**, *4*, 603–608. [CrossRef] [PubMed]

178. Crinelli, R.; Bianchi, M.; Gentilini, L.; Palma, L.; Magnani, M. Locked nucleic acids (LNA): Versatile tools for designing oligonucleotide decoys with high stability and affinity. *Curr. Drug Targets* **2004**, *5*, 745–752. [CrossRef] [PubMed]

179. Isomura, I.; Morita, A. Regulation of NF-κB signaling by decoy oligodeoxynucleotides. *Microbiol. Immunol.* **2006**, *50*, 559–563. [CrossRef] [PubMed]

180. Lin, Y.; Bai, L.; Chen, W.; Xu, S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. *Expert Opin. Ther. Targets* **2010**, *14*, 45–55. [CrossRef] [PubMed]

181. Takada, Y.; Bhardwaj, A.; Potdar, P.; Aggarwal, B.B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. *Oncogene* **2004**, *23*, 9247–9258. [CrossRef] [PubMed]

182. Brady, R.R.; Loveridge, C.J.; Dunlop, M.G.; Stark, L.A. C-src dependency of nsaid-induced effects on NF-κB-mediated apoptosis in colorectal cancer cells. *Carcinogenesis* **2011**, *32*, 1069–1077. [CrossRef] [PubMed]

183. Callejas, N.A.; Casado, M.; Bosca, L.; Martin-Sanz, P. Absence of nuclear factor kappab inhibition by nsaid in hepatocytes. *Hepatology* **2002**, *35*, 341–348. [CrossRef] [PubMed]

184. De Cicco, P.; Panza, E.; Ercolano, G.; Armogida, C.; Sessa, G.; Pirozzi, G.; Girino, G.; Wallace, J.L.; Iannar, A. Atb-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo. *Pharmacol. Res.* **2016**, *114*, 67–73. [CrossRef] [PubMed]

185. Ghanghas, P.; Jain, S.; Rana, C.; Sanyal, S.N. Chemopreventive action of non-steroidal anti-inflammatory drugs on the inflammatory pathways in colon cancer. *Biomed. Pharmacother.* **2016**, *78*, 239–247. [CrossRef] [PubMed]

186. Erstad, D.J.; Cusack, J.C., Jr. Targeting the NF-κB pathway in cancer therapy. *Surg. Oncol. Clin. N. Am.* **2013**, *22*, 705–746. [CrossRef] [PubMed]

187. Hoesel, B.; Schmid, J.A. The complexity of NF-κB signaling in inflammation and cancer. *Mol. Cancer* **2013**, *12*, 86. [CrossRef] [PubMed]

188. Adriaansen, J.; Vervoordeldonk, M.J.; Tak, P.P. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: Innovative vectors and therapeutic genes. *Rheumatology* **2006**, *45*, 656–668. [CrossRef] [PubMed]
189. Van de Loo, F.A.; Smeets, R.L.; van den Berg, W.B. Gene therapy in animal models of rheumatoid arthritis: Are we ready for the patients? *Arthritis Res. Ther.* 2004, 6, 183–196. [CrossRef] [PubMed]

190. Vervoordeldonk, M.J.; Aalbers, C.J.; Tak, P.P. Advances in local targeted gene therapy for arthritis: Towards clinical reality. *Future* 2008, 3, 307–309. [CrossRef]

191. Tak, P.P.; Gerlag, D.M.; Aupperle, K.R.; van de Geest, D.A.; Overbeek, M.; Bennett, B.L.; Boyle, D.L.; Manning, A.M.; Firestein, G.S. Inhibitor of nuclear factor kappab kinase beta is a key regulator of synovial inflammation. *Arthritis Rheum.* 2001, 44, 1897–1907. [CrossRef]

192. Sanlioglu, S.; Luleci, G.; Thomas, K.W. Simultaneous inhibition of Rac1 and IKK pathways sensitizes lung cancer cells to TNFα-mediated apoptosis. *Cancer Gene Ther.* 2001, 8, 897–905. [CrossRef] [PubMed]

193. Sanlioglu, A.D.; Koksal, I.T.; Karacay, B.; Baykara, M.; Luleci, G.; Sanlioglu, S. Adenovirus-mediated IKKβKA expression sensitizes prostate carcinoma cells to trail-induced apoptosis. *Cancer Gene Ther.* 2006, 13, 21–31. [CrossRef] [PubMed]

194. Karacay, B.; Sanlioglu, S.; Griffith, T.S.; Sandler, A.; Bonthius, D.J. Inhibition of the NF-κB pathway enhances trail-mediated apoptosis in neuroblastoma cells. *Cancer Gene Ther.* 2004, 11, 681–690. [CrossRef] [PubMed]

195. Friedman, J.M.; Horwitz, M.S. Inhibition of tumor necrosis factor alpha-induced NF-κB activation by the adenovirus e3-10.4/14.5k complex. *J. Virol.* 2002, 76, 5515–5521. [CrossRef] [PubMed]

196. Xu, M.Q.; Shuai, X.R.; Yan, M.L.; Zhang, M.M.; Yan, L.N. Nuclear factor-kappab decoy oligodeoxynucleotides attenuates ischemia/reperfusion injury in rat liver graft. *World J. Gastroenterol.* 2005, 11, 6960–6967. [CrossRef] [PubMed]

197. Akhtar, S.; Kole, R.; Juliano, R.L. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. *Life Sci.* 1991, 49, 1793–1801. [CrossRef] [PubMed]

198. De Stefano, D. Oligonucleotides decoy to NF-κB: Becoming a reality? *Discov. Med.* 2011, 12, 97–105. [PubMed]

199. Surabhi, R.M.; Gaynor, R.B. RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. *J. Virol.* 2002, 76, 12963–12973. [CrossRef] [PubMed]

200. Takaesu, G.; Surabhi, R.M.; Park, K.J.; Ninomiya-Tsuji, J.; Matsumoto, K.; Gaynor, R.B. TAK1 is critical for IκB kinase-mediated activation of the NF-κB pathway. *J. Mol. Biol.* 2003, 326, 105–115. [CrossRef]

201. Duan, J.; Friedman, J.; Nottingham, L.; Chen, Z.; Ara, G.; Van Waes, C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. *Mol. Cancer Ther.* 2007, 6, 37–50. [CrossRef] [PubMed]

202. Grimm, D.; Streetz, K.L.; Jopling, C.L.; Storm, T.A.; Pandey, K.; Davis, C.R.; Marion, P.; Salazar, F.; Kay, M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. *Nature* 2006, 441, 537–541. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).